Ajinomoto Bio Pharma Services
About Ajinomoto Bio Pharma Services
At Ajinomoto Bio-Pharma Services, our mission is to help improve the health of humankind. Our ultimate goal is to provide adaptive solutions, responsive service, trusted partnerships and peace of mind to our customers. Through innovation, accountability, compliance, communication and teamwork, we take pride in knowing our efforts are helping countless patients for years to come.
Stock Symbol:
AJINY
Stock Exchange:
OTCMKTS
Aji Bio-Pharma Animated Overview
77 articles about Ajinomoto Bio Pharma Services
-
Ajinomoto Bio-Pharma Services Announces Leadership Changes at US Facility
5/18/2023
Ajinomoto Bio-Pharma Services today announced leadership changes at the company's site in San Diego, effective immediately.
-
Ajinomoto Bio-Pharma Services Receives FDA Approval for High Potency Fill Line
4/19/2023
Ajinomoto Bio-Pharma Services is pleased to announce that the United States Food and Drug Administration (FDA) has approved the company's high potency vial line to manufacture a commercial product.
-
Ajinomoto Bio-Pharma Services Successfully Develops Highly Functional Ancestral RNA Ligase
2/22/2023
Ajinomoto Bio-Pharma Services is pleased to announce the development of a new enzyme for double strand oligonucleotide formation with high productivity.
-
Tony O'Neill Joins Ajinomoto Bio-Pharma Services' Leadership Team as Vice President of Compliance
1/25/2022
Ajinomoto Bio-Pharma Services, a leading global provider of bio-pharmaceutical contract development and manufacturing services, is pleased to announce that Tony O'Neill has joined Aji Bio-Pharma as Vice President of Compliance, US Operations.
-
Ajinomoto Bio-Pharma Services Expands Fill Finish Capacity with New Multi-Purpose Fill Suite
5/25/2021
Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, announced it will soon open a high speed multi-purpose fill finish line in its state-of-the-art commercial manufacturing facility located in San Diego, CA.
-
Ajinomoto Bio-Pharma Services and Humanigen Expand Manufacturing Agreement to Support Fill Finish for Investigational COVID-19 Therapeutic, Lenzilumab, Nearing Completion of Phase 3 Study - Jan 27, 2021
1/27/2021
Ajinomoto Bio-Pharma Services and Humanigen, Inc. announced the companies will be expanding their manufacturing agreement for the fill finish supply of lenzilumab, which is one of the few Phase 3 treatment options in development for patients hospitalized with COVID-19.
-
Ajinomoto Bio-Pharma Services Expands Small Molecule Manufacturing Capabilities at its India Facility
8/13/2020
Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce a major expansion of small molecule manufacturing capabilities with the addition of a new production facility in Visakhapatnam, India . Construction of the 8,500 square
-
Ajinomoto Bio-Pharma Services Introduces AJILITY Fast Track Platform for Drug Product Manufacturing
6/30/2020
Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce the launch of AJILITY™, a flexible and agile drug product manufacturing platform, designed to advance vaccines and therapies to market by minimizing time to production.
-
Ajinomoto Bio-Pharma Services Completes Acquisition of Granules OmniChem Joint Venture in India
6/2/2020
Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce that it has completed the acquisition of Granules OmniChem Private Limited, purchasing the remaining 50 percent ownership interest from its joint venture partner, Granules
-
Ajinomoto Bio-Pharma Services Signs Manufacturing Agreement with Humanigen for Lenzilumab, Currently in FDA-Approved Phase III Study for COVID-19
5/27/2020
Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce it has entered into a manufacturing agreement with Humanigen, Inc., for the fill finish supply of lenzilumab, currently being studied in a Phase III clinical trial in adult, hospita
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 27, 2020. -
Ajinomoto Bio-Pharma Services Announces Manufacturing Partnership with CytoDyn for Drug Product Used in COVID-19 Clinical Trials
5/5/2020
Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce it has entered into a manufacturing services agreement with CytoDyn Inc., a late stage biotechnology company, for the supply of the investigational new drug, leronlimab (PRO 140), wh
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 5, 2020. -
Trio Pharmaceuticals, Inc. and Ajinomoto Bio-Pharma Services Enter into a Development Collaboration for a Novel Antibody Therapeutic
4/30/2020
Trio Pharmaceuticals, Inc. ("TRIO"), a cancer therapeutics company developing novel dual action antibody drugs, TRIObody™, and novel dual action antibody drug conjugates, TRIObody Drug Conjugate™ (TDC™) and Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development a
-
Ajinomoto Bio-Pharma Services Announces Formation of External Advisory Board
3/10/2020
Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, announced today the formation of its External Advisory Board (EAB) to provide insight into industry trends and high-level advice to the Company's leadership team.
-
Great Place to Work is an organization whose goal it is to assure that all people in the U.S. have a great place to work by 2030. One category for certified companies is Biotechnology & Pharmaceuticals, which listed 36 companies. BioSpace organized these 36 companies into its BioSpace Hotbed Regi... -
GeneDesign Joins Ajinomoto Bio-Pharma Services and Opens Oligonucleotide API Development Center
4/8/2019
Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce that GeneDesign, Inc. has joined the global organization.
-
Jean-Baptiste Agnus Joins Ajinomoto Bio-Pharma Services' Global Leadership Team as Vice President of Sales and Marketing
4/3/2019
Ajinomoto Bio-Pharma Services, a leading global provider of bio-pharmaceutical contract development and manufacturing services, is pleased to announce that Jean-Baptiste Agnus has joined Aji Bio-Pharma as Vice President of Sales and Marketing.
-
Ajinomoto Bio-Pharma Services Announces Capital Expansion to Fuel Growth
3/12/2019
Ajinomoto Bio-Pharma Services, a leading global provider of bio-pharmaceutical contract development and manufacturing provided an update on several of its capital projects currently underway in both the United States and Belgium.
-
Ajinomoto and XL-protein Forge Strategic Alliance to Develop PASylated Therapeutics Applying the Corynex® Platform
12/18/2018
Ajinomoto Bio-Pharma Services and XL-protein GmbH, are pleased to announce a Strategic Alliance.